Melatonin and Myelodysplastic syndrome - a phase IV clinical study of FDA data

Summary:

Myelodysplastic syndrome is reported as a side effect among people who take Melatonin (melatonin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Revlimid, and have Mantle cell lymphoma.

The phase IV clinical study analyzes which people have Myelodysplastic syndrome when taking Melatonin. It is created by eHealthMe based on reports of 53,570 people who have side effects when taking Melatonin from the FDA, and is updated regularly.

What is Melatonin?

Melatonin has active ingredients of melatonin. It is often used in insomnia. eHealthMe is studying from 56,212 Melatonin users. Check the latest studies of Melatonin.

What is Myelodysplastic syndrome?

Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) is found to be associated with 826 drugs and 1,110 conditions by eHealthMe. Check the latest studies of Myelodysplastic syndrome.

On Jul, 20, 2026

53,570 people reported to have side effects when taking Melatonin.
Among them, 29 people (0.05%) have Myelodysplastic syndrome.

Could Melatonin cause Myelodysplastic syndrome?

Among these 29 people:

How long have people been on Melatonin when they have Myelodysplastic syndrome? *

What is the gender of people who have Myelodysplastic syndrome when taking Melatonin? *

female: 48.28 %
male: 51.72 %

What is the age of people who have Myelodysplastic syndrome when taking Melatonin? *

What are other drugs people take besides Melatonin? *

What are other side effects people have besides Myelodysplastic syndrome? *

Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 13.79%
Anaemia (lack of blood): 4 people, 13.79%
Thrombocytopenia (decrease of platelets in blood): 4 people, 13.79%
Neoplasm Malignant (cancer tumour): 3 people, 10.34%
Death: 3 people, 10.34%
Fever: 3 people, 10.34%
Fatigue (feeling of tiredness): 3 people, 10.34%
White Blood Cell Count Decreased: 2 people, 6.90%
Hypotension (abnormally low blood pressure): 2 people, 6.90%
Full Blood Count Abnormal: 2 people, 6.90%

What are the existing conditions these people have? *

Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 6 people, 20.69%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 17.24%
Type 2 Diabetes: 3 people, 10.34%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 10.34%
Indigestion: 3 people, 10.34%
Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 10.34%
Constipation: 3 people, 10.34%
Nausea And Vomiting: 3 people, 10.34%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 6.90%
Pain: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Melatonin and have Myelodysplastic syndrome?

- Check whether Myelodysplastic syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melatonin:

Melatonin (56,212 reports)

Browse all side effects of Melatonin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Myelodysplastic syndrome:

Myelodysplastic syndrome (826 drugs)

Browse all the conditions that are associated with Myelodysplastic syndrome:

Myelodysplastic syndrome (1,110 conditions)

Related publications that referenced our studies

Onder H, Arsava EM, Arat A, Topcuoglu MA, "Acute middle cerebral artery occlusion treated by thrombectomy in a patient with myelodysplastic syndrome and severe thrombocytopenia", Journal of vascular and interventional neurology, 2015 Jan .
Onder H, Arsava EM, Arat A, Topcuoglu MA, "Acute middle cerebral artery occlusion treated by thrombectomy in a patient with myelodysplastic syndrome and severe thrombocytopenia", Journal of vascular and interventional neurology, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on melatonin (the active ingredients of Melatonin) and Melatonin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.